Literature DB >> 15592417

Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

Photini Kiepiela1, Alasdair J Leslie, Isobella Honeyborne, Danni Ramduth, Christina Thobakgale, Senica Chetty, Prinisha Rathnavalu, Corey Moore, Katja J Pfafferott, Louise Hilton, Peter Zimbwa, Sarah Moore, Todd Allen, Christian Brander, Marylyn M Addo, Marcus Altfeld, Ian James, Simon Mallal, Michael Bunce, Linda D Barber, James Szinger, Cheryl Day, Paul Klenerman, James Mullins, Bette Korber, Hoosen M Coovadia, Bruce D Walker, Philip J R Goulder.   

Abstract

The extreme polymorphism in the human leukocyte antigen (HLA) class I region of the human genome is suggested to provide an advantage in pathogen defence mediated by CD8+ T cells. HLA class I molecules present pathogen-derived peptides on the surface of infected cells for recognition by CD8+ T cells. However, the relative contributions of HLA-A and -B alleles have not been evaluated. We performed a comprehensive analysis of the class I restricted CD8+ T-cell responses against human immunodeficiency virus (HIV-1), immune control of which is dependent upon virus-specific CD8+ T-cell activity. In 375 HIV-1-infected study subjects from southern Africa, a significantly greater number of CD8+ T-cell responses are HLA-B-restricted, compared to HLA-A (2.5-fold; P = 0.0033). Here we show that variation in viral set-point, in absolute CD4 count and, by inference, in rate of disease progression in the cohort, is strongly associated with particular HLA-B but not HLA-A allele expression (P < 0.0001 and P = 0.91, respectively). Moreover, substantially greater selection pressure is imposed on HIV-1 by HLA-B alleles than by HLA-A (4.4-fold, P = 0.0003). These data indicate that the principal focus of HIV-specific activity is at the HLA-B locus. Furthermore, HLA-B gene frequencies in the population are those likely to be most influenced by HIV disease, consistent with the observation that B alleles evolve more rapidly than A alleles. The dominant involvement of HLA-B in influencing HIV disease outcome is of specific relevance to the direction of HIV research and to vaccine design.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592417     DOI: 10.1038/nature03113

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  419 in total

1.  Correlates of spontaneous viral control among long-term survivors of perinatal HIV-1 infection expressing human leukocyte antigen-B57.

Authors:  Yanhua Tang; Sihong Huang; Jacqueline Dunkley-Thompson; Julianne C Steel-Duncan; Elizabeth G Ryland; M Anne St John; Rohan Hazra; Celia D C Christie; Margaret E Feeney
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

2.  Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.

Authors:  Jacques Fellay; Nicole Frahm; Kevin V Shianna; Elizabeth T Cirulli; Danilo R Casimiro; Michael N Robertson; Barton F Haynes; Daniel E Geraghty; M Juliana McElrath; David B Goldstein
Journal:  J Infect Dis       Date:  2011-01-28       Impact factor: 5.226

3.  Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity.

Authors:  Jaclyn K Wright; Vanessa L Naidoo; Zabrina L Brumme; Jessica L Prince; Daniel T Claiborne; Philip J R Goulder; Mark A Brockman; Eric Hunter; Thumbi Ndung'u
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

4.  Long-term control of HIV-1 in hemophiliacs carrying slow-progressing allele HLA-B*5101.

Authors:  Yuka Kawashima; Nozomi Kuse; Hiroyuki Gatanaga; Takuya Naruto; Mamoru Fujiwara; Sachi Dohki; Tomohiro Akahoshi; Katsumi Maenaka; Philip Goulder; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

5.  Changes in function of HIV-specific T-cell responses with increasing time from infection.

Authors:  Michel L Ndongala; Philomena Kamya; Salix Boulet; Yoav Peretz; Danielle Rouleau; Cécile Tremblay; Roger Leblanc; Pierre Côté; Jean-Guy Baril; RéJean Thomas; Sylvie Vézina; Mohamed R Boulassel; Jean-Pierre Routy; Rafick P Sékaly; Nicole F Bernard
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

6.  Different in vivo effects of HIV-1 immunodominant epitope-specific cytotoxic T lymphocytes on selection of escape mutant viruses.

Authors:  Hirokazu Koizumi; Masao Hashimoto; Mamoru Fujiwara; Hayato Murakoshi; Takayuki Chikata; Mohamed Ali Borghan; Atsuko Hachiya; Yuka Kawashima; Hiroshi Takata; Takamasa Ueno; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

7.  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.

Authors:  Diego Chowell; Luc G T Morris; Claud M Grigg; Jeffrey K Weber; Robert M Samstein; Vladimir Makarov; Fengshen Kuo; Sviatoslav M Kendall; David Requena; Nadeem Riaz; Benjamin Greenbaum; James Carroll; Edward Garon; David M Hyman; Ahmet Zehir; David Solit; Michael Berger; Ruhong Zhou; Naiyer A Rizvi; Timothy A Chan
Journal:  Science       Date:  2017-12-07       Impact factor: 47.728

8.  HIV peptidome-wide association study reveals patient-specific epitope repertoires associated with HIV control.

Authors:  Jatin Arora; Paul J McLaren; Nimisha Chaturvedi; Mary Carrington; Jacques Fellay; Tobias L Lenz
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-02       Impact factor: 11.205

9.  Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level.

Authors:  Golo Ahlenstiel; Kirsten Roomp; Martin Däumer; Jacob Nattermann; Martin Vogel; Jürgen K Rockstroh; Niko Beerenwinkel; Rolf Kaiser; Hans-Dieter Nischalke; Tilman Sauerbruch; Thomas Lengauer; Ulrich Spengler
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

10.  Host-specific adaptation of HIV-1 subtype B in the Japanese population.

Authors:  Takayuki Chikata; Jonathan M Carlson; Yoshiko Tamura; Mohamed Ali Borghan; Takuya Naruto; Masao Hashimoto; Hayato Murakoshi; Anh Q Le; Simon Mallal; Mina John; Hiroyuki Gatanaga; Shinichi Oka; Zabrina L Brumme; Masafumi Takiguchi
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.